ViaDerma, Inc. (VDRM)
| Market Cap | 123.37K -50.0% |
| Revenue (ttm) | 44.69K -99.7% |
| Net Income | -1.52M |
| EPS | -0.00 |
| Shares Out | 1.23B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 401,182 |
| Open | 0.0001 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | 0.000001 - 0.0080 |
| Beta | 0.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ViaDerma
ViaDerma, Inc., through its subsidiary, manufactures and sells pharmaceutical related products in the United States. The company’s lead product is Vitastem, a tetracycline and topical delivery technology for antibiotics to pain relief, skincare, and other. It is also developing various products for vitiligo, psoriasis, eczema, and other skin conditions using SkinPass topical delivery system, as well as antifungal, cosmetics, and pain management products. In addition, company develops anti-aging skin care, pain management, hair-loss, and toenail... [Read more]
Full Company ProfileFinancial Performance
In 2017, ViaDerma's revenue was $44,691, a decrease of -82.26% compared to the previous year's $251,981. Losses were -$1.52 million, 1146.6% more than in 2016.
Financial StatementsNews
ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance
LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working t...
ViaDerma Announces Shipment of 500,000 Units of its Flagship Product to Nigeria
LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a leader in innovative wound care solutions, is excited to announce that a shipment of 500,000 units of its flagship product,...
ViaDerma Finalizes Distribution Agreements in Dubai and Announces Six New Key Hires
LOS ANGELES, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), a leader in innovative wound care solutions, proudly announces the successful completion of pivotal distribution agreeme...
ViaDerma Provides Highlights of Quarterly Financial Report
LOS ANGELES, June 06, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is pleased to announce that on May 13, 2024, the Company released its quarterly report for the period ending March 31, 20...
ViaDerma Update on Stability Testing, Global Sales Distribution, National Licensing, Nupelo & More
LOS ANGELES, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is pleased to announce several new and exciting business updates for current and prospective shareholders, custom...
ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product
The Company unveils brand name for its planned minoxidil hair regrowth product The Company unveils brand name for its planned minoxidil hair regrowth product
ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product
The global hair restoration market is expected to reach $13.6 billion by 2028 The global hair restoration market is expected to reach $13.6 billion by 2028
ViaDerma Engages Intent Sciences to Power Up Digital Marketing & Brand Development
INTENT SCIENCES has a proven track record of achieving exceptional outcomes with growing businesses of all types & sizes. INTENT SCIENCES has a proven track record of achieving exceptional outcomes wi...
ViaDerma Successfully Completes Quality Control Testing of its New Vitastem Products
The first shipment of the new products has been received and online sales will resume The first shipment of the new products has been received and online sales will resume
ViaDerma Announces the Implementation of Internal Quality Control Measures for its New Vitastem Products
The Company's improved, new Vitastem products have recently begun large scale production The Company's improved, new Vitastem products have recently begun large scale production
ViaDerma's 2021 Annual Report Shows Strong Revenue Growth Over the Previous Year
Revenues increased by over 4000% in 2021, while liabilities decreased by more than 25% Revenues increased by over 4000% in 2021, while liabilities decreased by more than 25%
ViaDerma, Inc. Set to Launch Two New and Improved Versions of its Flagship Product, Vitastem and Vitastem Ultra
LOS ANGELES, Oct. 04, 2021 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM) is pleased to announce they are launching two new and improved formulas for its top selling product, Vitaste...
ViaDerma, Inc. Files Amended Financial Statements
LOS ANGELES, Aug. 24, 2021 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM) published a Quarterly Report for the three months ended March 31, 2021, on the OTC Markets website reporting...
ViaDerma, Inc. Provides Updates on Current Business Activities
The Company has finalized a ten-year $12 million licensing agreement with a Dubai Company The Company has finalized a ten-year $12 million licensing agreement with a Dubai Company
ViaDerma, Inc. Announces Expansion of its Current Licensing Agreement and Provides Additional Company Updates
Dr. Chris Otiko will be traveling to Dubai this month to finalize a 10-year, $12 million contract Dr. Chris Otiko will be traveling to Dubai this month to finalize a 10-year, $12 million contract
ViaDerma, Inc. Nearing Initial Order from Large Hospital Network
LOS ANGELES, May 13, 2021 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM), announced they are nearing the end of their discussions with a major healthcare network to finalize an initi...
ViaDerma, Inc. Provides Preliminary Revenue Estimates and Highlights for its Record Breaking 1st Quarter
The Company realized significant Q1 revenue growth due to increased online retail sales and proceeds from a licensing agreement The Company realized significant Q1 revenue growth due to increased onli...
ViaDerma, Inc. Announces the Payment of all Toxic Convertible Notes and Has Become Debt Free
The Company expects to completely self-fund all operations going forward The Company expects to completely self-fund all operations going forward
ViaDerma, Inc. Completes a Licensing Agreement with a Group of Affiliate Wound Care Medical Practices Operating in Six States
LOS ANGELES, Jan. 21, 2021 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM), announces the completion of a licensing agreement with a group of affiliated wound care medical practices. ...
ViaDerma Inc., Provides Review of 2020 and Looks Forward to 2021
LOS ANGELES, Jan. 13, 2021 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), President and CEO, Dr. Christopher Otiko offers a review of 2020 and provides a summary of his expectations ...